Certara, Inc. CERT R3KPHARMA
Company Overview
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 12.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.31.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $418.84M (+8.7% YoY); net profit $-1.59M.
- Trailing 12 Months Year-on-year growth — revenue +1.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.33% |
| 1 Year: | 1.00% |
Stock Price Performance
| 1 Year: | -30.71% |
| 6 Months: | +9.94% |
| 3 Months: | +48.28% |
| 1 Month: | -5.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)44.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 43.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CERT Certara, Inc. R3KPHARMA | 7.74 | -55.29 | $1.18B | 0.00% | 1.50% | -2.21% | 12.33% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.45M | 61.12M | 60.32M | 66.72M | 70.10M | 73.94M | 81.55M | 82.76M | 84.70M | 90.30M | 90.45M | 85.58M | 96.65M | 93.31M | 94.82M | 106.00M | 104.57M | 104.62M | 106.92M | 93.27M |
| Operating Income | 8.00M | 13.61M | 7.50M | 5.62M | 5.27M | -761.00K | 6.13M | 4.15M | 10.86M | 7.44M | 13.04M | -52.78M | -1.29M | -9.04M | 2.59M | 7.62M | 9.55M | 3.00M | -4.30M | -196.00K |
| Net Income | 1.05M | 2.78M | 1.23M | 1.05M | -2.86M | -1.76M | 2.21M | -589.00K | 3.94M | 1.36M | 4.71M | -48.97M | -4.68M | -12.57M | -1.37M | 4.74M | -1.97M | 1.52M | -8.76M | -55.27M |
| Diluted EPS | 0.01 | 0.02 | 0.01 | 0.01 | -0.02 | -0.01 | 0.01 | 0.00 | 0.02 | 0.01 | 0.03 | -0.31 | -0.03 | -0.08 | -0.01 | 0.03 | -0.01 | 0.01 | -0.06 | -0.36 |
| R&D Expense | 2.88M | 2.97M | 3.29M | 4.71M | 4.63M | 4.53M | 7.55M | 7.74M | 6.32M | 9.29M | 7.89M | 8.98M | 11.99M | 9.07M | 8.27M | 10.52M | 8.97M | 10.27M | 12.29M | 9.71M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 208.51M | 243.53M | 286.10M | 335.64M | 354.34M | 385.15M | 418.84M |
| Operating Income | 19.61M | -24.42M | 13.58M | 32.52M | -40.77M | -1.73M | 21.02M |
| Net Income | -8.93M | -49.40M | -13.27M | 14.73M | -55.36M | -12.05M | -1.59M |
| Diluted EPS | -0.07 | -0.37 | -0.09 | 0.09 | -0.35 | -0.08 | -0.01 |
| R&D Expense | 11.63M | 19.64M | 20.38M | 28.20M | 34.17M | 37.10M | 41.04M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.27B | 1.51B | 1.57B | 1.56B | 1.58B | 1.56B |
| Total Equity | 492.77M | 492.05M | 822.13M | 1.04B | 1.08B | 1.05B | 1.06B | 1.06B |
| Cash & Equivalents | - | 29.26M | 271.38M | 185.80M | 236.59M | 234.95M | 179.18M | 189.39M |
| Long Term Debt | - | - | 294.10M | 291.75M | 289.99M | 288.22M | 292.43M | 290.13M |
| Total Liabilities | - | - | 447.27M | 469.88M | 493.26M | 516.30M | 516.45M | 493.79M |
| Current Liabilities | - | - | 75.34M | 92.22M | 103.16M | 130.02M | 146.09M | 153.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 38.02M | 44.81M | 60.39M | 92.54M | 82.75M | 80.47M | 96.33M |
| Investing Cash Flow | -9.52M | -8.61M | -269.92M | -27.84M | -79.55M | -112.37M | -26.56M |
| Financing Cash Flow | -8.49M | 208.21M | 123.39M | -7.36M | -9.45M | -21.01M | -63.99M |
| Capital Expenditure | -2.11M | -863.00K | -1.14M | -1.43M | -1.78M | -1.62M | -1.76M |
| Free Cash Flow | 35.92M | 43.95M | 59.24M | 91.11M | 80.98M | 78.84M | 94.56M |
| Share Buybacks | 703.00K | 1.08M | - | - | 0 | 0 | 42.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | 9.4% | -10.0% | 4.7% | 9.7% | -11.5% | -0.4% | 5.0% |
| Net Margin % | -4.3% | -20.3% | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% |
| ROE % | -1.8% | -6.0% | -1.3% | 1.4% | -5.3% | -1.1% | -0.2% |
| ROCE % | - | -2.0% | 1.0% | 2.2% | -2.8% | -0.1% | 1.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.34% | 18.82M | $158.45M |
| 2 | Deerfield Management Company, L.P | 4.93% | 7.51M | $63.26M |
| 3 | Haveli Investment Management LLC | 4.85% | 7.40M | $62.31M |
| 4 | Jefferies Financial Group Inc. | 4.65% | 7.09M | $59.71M |
| 5 | Vanguard Portfolio Management LLC | 4.63% | 7.06M | $59.41M |
| 6 | Dimensional Fund Advisors LP | 3.95% | 6.02M | $50.71M |
| 7 | Vanguard Capital Management LLC | 3.46% | 5.28M | $44.48M |
| 8 | State Street Corporation | 3.16% | 4.82M | $40.60M |
| 9 | Wasatch Advisors LP | 2.82% | 4.30M | $36.20M |
| 10 | Geode Capital Management, LLC | 2.06% | 3.14M | $26.45M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CERT
Certara (NASDAQ: CERT) officer lines up $300K stock sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOWFl0ZDNhLVA3Nzdud3c0UlYxNDFYdTN3TFV3c3dwV2syNlFIT1REaEZUemZOOUdoZmV0UGxpejIycUxJci11NHFhR1pwbjdfZnAxaTN4SXUyWDc3UVBqLWFJZElseEdpSnUxUWE0czl4VTFCZ01tMHR2ZnZwYkpoVXJKcWlwMmJxR0Fqc0…
(CERT) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPc2VqSlo1aG1qWEQwN2M2VDlCQ3ZQdVVUZnNuSWJaSkpTdVB2czV4Q0plSUxyTEZsbEhKQmhTR19sSWVFR2ZrWFRoaVhPbjJWeFRiTHVNN0ZESTJtc2NCeUZCS1FiQ2g5UVMzSS1aOURtRmZGaWpTYXpSQU5KSFp1bjg0UW5LTFFTZU94T1…
Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPYlVnYURjd3J5VEMxME1zRjdVZ1FwZlh4T0dDU0xKZ3B0UjNfYmVuSjBaUjFjZWRjZ2RKbFJGOFMxTElHWjFLWXpYa2t6dHFxVi1tc1hpSGM3M3lSSjZVTTVIT3A4eGZPc0NwSjNXYkF3QlU5Xzc0V2d4TGFmdVI1NzhSLTJ4ZzFLY290b0…
Cerrado Gold (CERT) Stock Chart and Price History 2026 $CERT - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5BUjdpcGZRcU9jeTBlYk82dktmd3NrdlRENHJKVGd4eEZhZVBIQS0tME1va3NTUm93a0FUVlVYSGx0OGpSZjVJTm1qa0xKZURMbnNZVkJQM3dlZzMyVkE?oc=5" target="_blank">Cerrado Gold (CERT) Stock Chart and Pric…
CERT Stock Price and Chart — TSXV:CERT - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFByT1I5eEl4cjQzdkg3LUZUMTBaaHVOc05pR2NaQUdqWXBBVTVzVkJNREdtZl9aR0ZaRUVGYk12bzZVZlA3bnl5N2tMS2pOR2h4SU5tVlNPd0VDUQ?oc=5" target="_blank">CERT Stock Price and Chart — TSXV:CERT</a>&nb…
Cerrado Gold Elevates Chris MacInnis to Vice President, Geology - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOMzZ3dzNrUUpkQnhUZ2EwOXFIVVluMG4wSUpCdHB3ekNvM2phUkVDZzJUekF1VVlmSkdNREs5OTQ4Vk5JMjl4dTUwbTFtUHU1UnFnMzhpQjZ3eXpqVVk2ZW9aRmVfV1g4cHV1cW95YmdJeGZWektMdzdFS2g1OGpLTmxPVjJzTG5qUEVOUX…
CERT — Frequently Asked Questions
What is the current share price of Certara, Inc. (CERT)?
As of 2026-09-19 21:16 PDT, Certara, Inc. (CERT) trades at $7.74 on NasdaqGS. Its 52-week range is $4.48 to $13.60.
What is the market capitalisation of CERT?
Certara, Inc. (CERT) has a market capitalisation of $1.18B on NasdaqGS.
What is the P/E ratio of CERT?
CERT trades at a trailing price-to-earnings (P/E) ratio of -55.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.20.
What is the return on equity (ROE) of CERT?
CERT has a return on equity (ROE) of -2.21%. Its return on capital employed (ROCE) is 1.50%.
Is CERT a good stock to buy?
This page provides a data-driven analysis of Certara, Inc. (CERT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.